When stem cells meet immunoregulation

International Immunopharmacology

Volumn 9, Issue 5, 2009, Pages 596-598

  Tasso, Roberta ^a   Pennesi, Giuseppina ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b ADVANCED BIOTECHNOLOGY CENTER   (Italy)

Author keywords

Adult stem cells; Immunoregulation; Mesenchymal stem cells; Stem cells

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ADIPOCYTE; ANTIGEN SPECIFICITY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INTERACTION; CELL ISOLATION; CELL LINEAGE; EMBRYONIC STEM CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOMODULATION; IMMUNOREGULATION; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOCYTE; PRIORITY JOURNAL; RECIPIENT; REGULATORY T LYMPHOCYTE; STEM CELL; TISSUE DIFFERENTIATION; ADULT STEM CELL; ANIMAL; CARTILAGE CELL; CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMA CELL; PHYSIOLOGY;

ADIPOCYTES; ADULT STEM CELLS; ANIMALS; ANTIGENS, CD4; CELL DIFFERENTIATION; CHONDROCYTES; EMBRYONIC STEM CELLS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOMODULATION; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELLS; OSTEOCYTES; T-LYMPHOCYTES, REGULATORY; MESENCHYMAL STROMAL CELLS;

EID: 63549090131     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.01.014     Document Type: Article

References (50)

1. Batten P., Rosenthal N.A., and Yacoub M.H. Immune response to stem cells and strategies to induce tolerance. Philos Trans R Soc Lond B Biol Sci 362 (2007) 1343-1356
2. Chidgey A.P., Layton D., Trounson A., and Boyd R.L. Tolerance strategies for stem-cell-based therapies. Nature 453 (2008) 330-337
3. Tasso R., Augello A., Carida M., Postiglione F., Tibiletti M.G., Bernasconi B., et al. Development of sarcomas in mice implanted with mesenchymal stem cells seeded onto bioscaffolds. Carcinogenesis 30 (2009) 150-157 10.1093/carcin/bgn234
4. Hori J., Ng T., Shatos M., Klassen H., Streilein J., Young M.G., et al. Neural progenitor cells lack immunogenicity and resist destruction as allografts. Stem Cells 21 (2003) 405-416
5. Uccelli A., Moretta L., and Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol (2008) 10.1038/nri2395
6. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
7. Bianco P., Riminucci M., Gronthos S., and Robey P. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 19 (2001) 180-192
8. Grove J.E., Bruscia E., and Krause D.S. Plasticity of bone marrow-derived stem cells. Stem Cells 22 (2004) 487-500
9. Bianco P., Robey P.G., and Simmons P.J. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2 (2008) 313-319
10. Tyndall A., Walker U.A., Cope A., Dazzi F., De Bari C., Fibbe W., et al. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther 9 (2007) 301
11. Kuznetsov S., Mankani M., Gronthos S., Satomura K., Bianco P., and Robey P.G. Circulating skeletal stem cells. J Cell Biol 153 (2001) 1133-1139
12. Jiang Y., Jahagirdar B., Reinhardt R., Schwartz R., Keenek C., Ortiz-Gonzalezk X.R., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418 (2002) 41-49
13. Potian J.A., Aviv H., Ponzio N.M., Harrison J.S., and Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 171 (2003) 3426-3434
14. Augello A., Tasso R., Negrini S.M., Amateis A., Indiveri F., Cancedda R., et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 35 (2005) 1482-1490
15. Liu C.H., and Hwang S.M. Cytokine interactions in mesenchymal stem cells from cord blood. Cytokine 32 (2005) 270-279
16. Stagg J. Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens 69 (2007) 1-9
17. Horwitz E., Prockop D., Fitzpatrick L., Koo W., Gordon P., Neel M., et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 5 (1999) 309-313
18. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., and Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75 (2003) 389-397
19. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., and Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57 (2003) 11-20
20. Maitra B., Szekely E., Gjini K., Laughlin M., Dennis J., Haynesworth S.E., et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 33 (2004) 597-604
21. Klyushnenkova E., Mosca J.D., Zernetkina V., Majumdar M.K., Beggs K.J., Simonetti D.W., et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 12 (2005) 47-57
22. Augello A., Tasso R., Negrini S.M., Cancedda R., and Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 56 (2007) 1175-1186
23. Bianco P., Gehron Robey P., Pennesi G., and Cancedda R. Cell source. In: van Blitterswijk C., Thomsen P., Lindahl A., Hubbell J., Williams D.F., Cancedda R., de Bruijn J.D., and Sohier J. (Eds). Tissue Engineering (2008), Elsevier Inc., Oxford, UK 279-306
24. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99 (2002) 3838-3843
25. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30 (2002) 42-48
26. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101 (2003) 3722-3729
27. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106 (2005) 1755-1761
28. Krampera M., Cosmi L., Angeli R., Pasini A., Liotta F., Andreini A., et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24 (2006) 386-398
29. Glennie S., Soeiro I., Dyson P.J., Lam E.W., and Dazzi F. Bone marrow mesenchymal stem cells induce division arrest energy of activated T cells. Blood 105 (2005) 2821-2827
30. Sato K., Ozaki K., Oh I., Meguro A., Hatanaka K., Nagai T., et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109 (2007) 228-234
31. Rasmusson I., Ringden O., Sundberg B., and Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76 (2003) 1208-1213
32. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., and Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103 (2004) 4619-4621
33. Aggarwal S., and Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105 (2005) 1815-1822
34. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 107 (2006) 367-372
35. Sotiropoulou P.A., Perez S.A., Gritzapis A.D., Baxevanis C.N., and Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24 (2006) 74-85
36. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., and Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107 (2006) 1484-1490
37. Poggi A., Prevosto C., Massaro A.M., Negrini S., Urbani S., Pierri I., et al. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J Immunol 175 (2005) 6352-6360
38. Zhang W., Ge W., Li C., You S., Liao L., Han Q., et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 13 (2004) 263-271
39. Maccario R., Podesta M., Moretta A., Cometa A., Comoli P., Montagna D., et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90 (2005) 516-525
40. Beyth S., Borovsky Z., Mevorach D., Liebergall M., Gazit Z., Aslan H., et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105 (2005) 2214-2219
41. Jiang X.X., Zhang Y., Liu B., Zhang S.X., Wu Y., Yu X.D., et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105 (2005) 4120-4126
42. Ramasamy R., Fazekasova H., Lam E.W., Soeiro I., Lombardi G., and Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 83 (2007) 71-76
43. Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., and Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31 (2003) 890-896
44. Arinzeh T.L., Peter S.J., Archambault M.P., van den Bos C., Gordon S., Kraus K., et al. Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect. J Bone Joint Surg Am 85-A (2003) 1927-1935
45. Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 26 (2008) 212-222
46. Djouad F., Bony C., Apparailly F., Louis-Plence P., Jorgensen C., and Noel D. Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation 82 (2006) 1060-1066
47. Paust S., Lu L., McCarty N., and Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci U S A 101 (2004) 10398-10403
48. Nasef A., Chapel A., Mazurier C., Bouchet S., Lopez M., Mathieu N., et al. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr 13 (2007) 217-226
49. Powrie F., Carlino J., Leach M.W., Mauze S., and Coffman R.L. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med 183 (1996) 2669-2674
50. Asseman C., Mauze S., Leach M.W., Coffman R.L., and Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190 (1999) 995-1004